Profiling of gene fusion involving targetable genes in Chinese gastric cancer

Table 1 Clinical characteristics in targetable gene fusion-positive and -negative patients

Variables	Total, n	Fusion involving targetable genes		P value
		Positive, n (%)	Negative, n (%)
Sex				0.293
Female	310	3 (0.97)	307 (99.03)
Male	644	13 (2.02)	631 (97.98)
Age, yr				0.463
≤ 60	451	6 (1.56)	445 (98.44)
> 60	503	10 (1.98)	493 (98.01)
MSI status				0.551
MSI-H	46	1 (2.17)	45 (97.93)
MSS	908	15 (1.65)	893 (98.35)
TMB				0.217
Median TMB score	2.92	5.63	2.83

Age, sex, microsatellite instability status, and tumor mutational burden between fusion-positive and -negative patients were compared. The one-tailed P value for Fisher’s exact test was calculated. MSI-H: Microsatellite instability-high; MSS: Microsatellite stability; TMB: Tumor mutational burden.

Table 2 List of gene fusions involving targetable genes in Chinese patients with gastric cancer and drugs under clinical trial or approved by the Food and Drug Administration

Patients ID	Fusion gene	5' partner gene				3' partner gene				Variant frequency, %	Functional domain is included or not	Targeted drugs
		Gene name	Chromosome	Last observed exon	Breakpoint	Gene name	Chromosome	First observed exon	Breakpoint
Patient 01	RARA-PGAP3	RARA	17	3	38504951	PGAP3	17	8	37828020	24.1	Partially include	Tamibarotene targeting RARA fusion2
Patient 01	KRTAP9-7-RARA	KRTAP9-7	17	downstream	39437039	RARA	17	3	38499547	56.9	Completely include	Tamibarotene targeting RARA fusion2
Patient 02	RARA-KRT13	RARA	17	2	38491648	KRT13	17	8	39657269	29.2	Partially include	Tamibarotene targeting RARA fusion2
Patient 02	RARA-ETV4	RARA	17	2	38499726	ETV4	17	5	41621243	76	Partially include	Tamibarotene targeting RARA fusion2
Patient 03	RARA-IKZF3	RARA	17	2	38504120	IKZF3	17	2	38009555	18.4	Partially include	Tamibarotene targeting RARA fusion2
Patient 04	FGFR2-PDE2A	FGFR2	10	17	123241248	PDE2A	11	7	72307251	1.4	Completely include	Pemigatinib; Erdafitinib targeting FGFR fusion1
Patient 05	FGFR2-intergenic	FGFR2	10	17	123242196	intergenic	10	-	123394107	16.6	Completely include	Pemigatinib; Erdafitinib targeting FGFR fusion1
Patient 06	FGFR2-intergenic	FGFR2	10	17	123240841	intergenic	10	-	122793842	4.2	Completely include	Pemigatinib; Erdafitinib targeting FGFR fusion1
Patient 07	FGFR2-SHTN1	FGFR2	10	17	123242528	SHTN1	10	6	118709305	5.1	Completely include	Pemigatinib; Erdafitinib targeting FGFR fusion1
Patient 08	FGFR3-PHTF2	FGFR3	4	18	1808927	PHTF2	7	11	77567982	3.3	Completely include	Pemigatinib; Erdafitinib targeting FGFR fusion1
Patient 09	STIM2-BRAF	STIM2	4	11	27012641	BRAF	7	9	140487929	12.7	Completely include	Selumetinib targeting BRAF fusion1
Patient 09	STIM2-BRAF	STIM2	4	11	27013243	BRAF	7	10	140486103	1.1	Completely include	Selumetinib targeting BRAF fusion1
Patient 09	TBC1D19-BRAF	TBC1D19	4	4	26629603	BRAF	7	10	140486782	6.5	Completely include	Selumetinib targeting BRAF fusion1
Patient 10	TES-MET	TES	7	1	115867013	MET	7	2	116332227	0.7	Completely include	Crizotinib targeting MET fusion1
Patient 11	MET-TES	MET	7	21	116436166	TES	7	4	115889445	24.6	Not include	Crizotinib targeting MET fusion1
Patient 12	EML4-ALK	EML4	2	6	29447382	ALK	2	20	42498662	3.5	Completely include	Crizotinib; ceritinib targeting ALK fusion1
Patient 13	OPALIN-RET	OPALIN	10	6	98104545	RET	10	11	43610099	5.46	Completely include	Pralsetinib targeting RET fusion1
Patient 14	ARHGAP10-NTRK2	ARHGAP10	4	1	148716754	NTRK2	9	16	87476645	15.3	Completely include	Larotrectinib targeting NTRK2 fusion1
Patient 15	NRG1-FDFT1	NRG1	8	12	32617907	FDFT1	8	8	11685375	8.9	Partially include	MCLA-128 targeting NRG1 fusion2
Patient 16	EGFR-SEPTIN14	EGFR	7	25	55269173	SEPTIN14	7	10	55871179	9.6	Completely include	Afatinib targeting EGFR fusion2

¹FDA-approved drugs targeting gene fusions.

²Drugs targeting gene fusions are under clinical trials.